Cancer Treatment

A new artificial intelligence-powered cancer detection tool is under review by the Food and Drug Administration and could become the first device of its kind approved in the U.S., according to a Newsweek report. The company behind the technology said it hopes to launch the tool next year if it...

British drugmaker GSK plc (NYSE:GSK) is betting on blockbuster potential for its experimental cancer therapy Mo-rez, after early trial data showed the drug shrank tumors in patients with advanced, hard-to-treat gynecological cancers. “Do we think it would be a blockbuster? Yes, absolutely,...

GitLab Inc. (NASDAQ:GTLB) co-founder Sid Sijbrandij has reframed his fight against a rare and aggressive cancer as an engineering challenge, leveraging artificial intelligence, genomic sequencing and real-time scientific research to explore personalized treatment paths. AI Meets Medicine In A...

The U.S. Food and Drug Administration (FDA) on Friday approved Regeneron Pharmaceuticals Inc. (NASDAQ:REGN) and Sanofi SA’s (NASDAQ:SNY) Dupixent (dupilumab) for adult patients with bullous pemphigoid (BP), a rare, chronic autoimmune skin disorder. BP primarily affects elderly...

The Food and Drug Administration approved Amgen Inc‘s (NASDAQ:AMGN) Lumakras (sotorasib) in combination with Vectibix (panitumumab) for KRAS G12C-mutated metastatic colorectal cancer (mCRC), who have received prior fluoropyrimidine-, oxaliplatin- and irinotecan-based chemotherapy.  Approval...

Pfizer Inc (NYSE: PFE) is among the many pharmaceutical companies that turned to oncology in response to sinking demand for its COVID-19 products and near patent expiration dates for its several top-sellers. At the end of 2023, Pfizer completed its acquisition of Seagen Inc. (NASDAQ: SGEN),...

In a recent announcement, 23andMe Holding Co. (NASDAQ:ME) has disclosed that the U.S. Food and Drug Administration (FDA) has given the green light to its investigational new drug application for 23ME-01473 (‘1473), a natural killer (NK) cell activator designed to combat cancer. What Happened...

Key takeaways: GenScript Biotech said it lost up to $519 million last year, with its Legend Biotech unit accounting for nearly 70% of that Legend Biotech’s Cilta-cel CAR-T cell therapy product was approved by the FDA on Monday, and could become a major cash cow for GenScript Biotech By...

The following post was written and/or published as a collaboration between Benzinga’s in-house sponsored content team and a financial partner of Benzinga. Since its establishment in 2014 by founding company Fortress Biotech, Inc. (NASDAQ: FBIO), biopharmaceutical company Checkpoint...

Valeant Pharmaceuticals Intl Inc (NYSE: VRX) shares gained 2 percent Monday morning after the company confirmed the Food and Drug Administration approved its bowel-cleansing preparation product. What Happened Valeant said the FDA granted approval for PLENVU, the company's polyethylene...

Shares of Endocyte, Inc. (NASDAQ: ECYT) were trading higher by more than 60 percent Tuesday afternoon at $5.82 on top of Monday's monster triple-digit-percentage return gain, but some analysts see even more upside. Wedbush's David Nierengarten upgraded Endocyte's stock rating Neutral to Outperform...

Merck & Co., Inc. (NYSE: MRK)'s KEYTRUDA is a therapy used to combat a form of skin cancer called melanoma. It can also be used to treat a kind of lung cancer called non-small cell lung cancer. The U.S. Food and Drug Administration announced on Nov. 28, 2016, it has granted a Priority Review...

Juno Therapeutics Inc (NASDAQ: JUNO) announced late Thursday it has received notice from the U.S. Food and Drug Administration that it has placed a clinical hold on its Phase II clinical trial of JCAR015 in patients with relapsed or refractory B cell acute lymphoblastic leukemia. The trial,...

Shares of OXiGENE Inc (NASDAQ: OXGN), a nano-cap biopharmaceutical company that focuses on the development of vascular disrupting agents for the treatment of cancer, surged higher by more than 65 percent early Tuesday morning. Investors and traders reacted to OXiGENE's announcement that the "...